Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - pravastatin sodium, quantity: 80 mg - tablet, uncoated - excipient ingredients: povidone; microcrystalline cellulose; lactose monohydrate; heavy magnesium oxide; croscarmellose sodium; magnesium stearate; iron oxide yellow - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.,2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 ? 5.5 mmol/l) serum cholesterol levels.,3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials).,4. pravastatin is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; heavy magnesium oxide; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; povidone - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.,2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 ? 5.5 mmol/l) serum cholesterol levels.,3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials).,4. pravastatin is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; heavy magnesium oxide; croscarmellose sodium; iron oxide yellow; povidone - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.,2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 ? 5.5 mmol/l) serum cholesterol levels.,3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials).,4. pravastatin is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; iron oxide yellow; heavy magnesium oxide; lactose monohydrate; magnesium stearate; povidone - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.,2. pravastatin is indicated in patients with previous myocardial infarction including those who have normal (4.0 ? 5.5 mmol/l) serum cholesterol levels.,3. pravastatin is indicated in patients with unstable angina pectoris (see clinical trials).,4. pravastatin is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - pravastatin sodium - tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

wpr healthcare limited - pravastatin sodium - tablet - 40 milligram(s) - hmg coa reductase inhibitors; pravastatin

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 10 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 20 mg - lipid modifying agents

Malta - English - Medicines Authority

basics gmbh hemmelrather weg 201 51377 leverkusen, germany - atorvastatin - film-coated tablet - atorvastatin 40 mg - lipid modifying agents